Biomimetic Innovation Ltd is an affiliate of PBC Biomed; a medical device company involved in design, development, and manufactoring headquartered in Shannon, Ireland and with offices in Memphis, Tennessee and Chamonix, France. Its mission is to accelerate medical innovation through the development of a new bone adhesive technology based on biology called OsStic®. Resulting from a decade long collaboration between GP Bio Ltd and PBC Biomed Ltd, both with extensive expertise in the area of biomaterials and bone repair, Biomimetic Innovations aims to commercialise OsStic® in a multitude of applications as a biomimetic adhesive for skeletal and soft tissue repair.
OsStic® Technology was developed to enhance the bodies’ natural healing process using biomimetic agents. OsStic® technology is currently being studied in both soft and hard tissue applications in human and veterinary indications to address current surgical limitations.
OsStic® Benefits Clinicians & Patients
Based on extensive in-vivo studies, OsStic® offers trauma, spinal and dental clinicians and their patients, the opportunity to benefit from the disruptive attributes of this technology
Enhanced structural stability
Faster remodeling into bone
Immediate implant stabilization in poor bone quality
A biological approach to provisional fixation
Adhesive properties in a wet environment
Promoting earlier patient mobilization
OsStic® Receives FDA 'Breakthrough Device' Designation in 2023
OsStic® Synthetic Injectable Bone Void Filler is a structural, mechanically enhanced bioadhesive for reduction, provisional fixation, or void filling of peri-articular fractures or defects to enhance structural stability where standard fixation alone cannot provide sufficient support for functional mobilization.
Stay Informed
News
Publications
Developments
Contact Us
